重症COVID-19患者恢复期血浆输注的安全性与剂量反应:II期随机对照试验方案结构化摘要
该II期多中心随机对照试验评估恢复期血浆(CP)输注治疗重症COVID-19患者的安全性、疗效及剂量反应,比较标准治疗、标准治疗+200ml CP和标准治疗+400ml CP三组,计划招募60例受试者(每组20例),主要结局为7天内临床改善时间或至出院时间(以较晚者为准)及住院死亡率。
要点
- 重症COVID-19定义基于WHO临床标准,包括呼吸频率>30次/分、SpO2≤88%等。
- 试验设三个臂:标准治疗、标准治疗+200ml CP、标准治疗+400ml CP。
- 主要结局为7天内临床改善时间或至出院时间(以较晚者为准)及住院死亡率。
核心结论
- 该II期试验旨在初步评估恢复期血浆治疗重症COVID-19的安全性和疗效,为设计更大规模研究提供数据。
研究设计与样本
- 多中心、多臂II期随机对照试验,计划招募60例年龄和性别匹配的RT-PCR确诊重症COVID-19患者,按1:1:1随机分配至三个治疗臂。
- 纳入标准包括呼吸频率>30次/分、严重呼吸窘迫或SpO2≤88%或PaO2/FiO2≤300 mmHg、影像学双侧肺浸润、收缩压<90 mmHg或舒张压<60 mmHg或需要呼吸机支持。
- 排除标准包括年龄<18岁、孕妇及哺乳期妇女、既往对血浆过敏史、已接受过其他来源血浆治疗者。
- 随机化由不参与患者护理或评估的人员使用计算机生成的随机数字表进行,分配比例为1:1:1。
- 研究为开放标签设计,但主要和次要结局(氧饱和度、PaO2/FiO2、血压、特定日实验室检查)采用客观自动化方法记录。
关键数值与推荐
- 恢复期血浆供者需满足:体温正常超过3天、呼吸道症状缓解、间隔至少24小时连续两次痰SARS-CoV-2 RT-PCR阴性、发病后22至35天、中和抗体滴度≥1:160。
- 干预组分别接受单次200ml或400ml恢复期血浆输注,对照组接受标准治疗。
- 主要结局为治疗7天内临床改善时间或至出院时间(以较晚者为准)及住院死亡率。
- 次要结局包括实验室参数改善(中性粒细胞/淋巴细胞比值、CRP、血清铁蛋白、SGPT、SGOT、血清肌酐和影像学)、住院时长、ICU停留时长、死亡比例降低、呼吸机需求及氧疗和呼吸机支持持续时间。
临床怎么用
- 该方案为重症COVID-19患者恢复期血浆治疗的剂量选择(200ml vs 400ml)和安全性评估提供初步随机对照证据。
局限性
- 样本量较小(60例),且因无既往类似研究数据,无法进行样本量计算,仅为II期探索性研究。
- 研究为开放标签设计,可能存在实施偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: General: To assess the safety, efficacy and dose response of convalescent plasma (CP) transfusion in severe COVID-19 patients Specific: a. To identify the appropriate effective dose of CP therapy in severe patients b. To identify the efficacy of the therapy with their end point based on clinical improvement within seven days of treatment or until discharge whichever is later and in-hospital mortality c. To assess the clinical improvement after CP transfusion in severe COVID-19 patients d. To assess the laboratory improvement after CP transfusion in severe COVID-19 patients TRIAL DESIGN: This is a multicentre, multi-arm phase II Randomised Controlled Trial. PARTICIPANTS: Age and sex matched COVID-19 positive (by RT-PCR) severe cases will be enrolled in this trial. Severe case is defined by the World Health Organization (W.H.O) clinical case definition. The inclusion criteria are 1. Respiratory rate > 30 breaths/min; PLUS 2. Severe respiratory distress; or SpO2 ≤ 88% on room air or PaO2/FiO2≤ 300 mm of Hg, PLUS 3. Radiological (X-ray or CT scan) evidence of bilateral lung infiltrate, AND OR 4. Systolic BP < 90 mm of Hg or diastolic BP <60 mm of Hg. AND/OR 5. Criteria 1 to 4 AND or patient in ventilator support Patients' below18 years, pregnant and lactating women, previous history of allergic reaction to plasma, patients who have already received plasma from a different source will be excluded. Patients will be enrolled at Bangabandhu Sheikh Mujib Medical University (BSMMU) hospital, Dhaka medical college hospital (DMCH) and Mugda medical college hospital (MuMCH). Apheretic plasma will be collected at the transfusion medicine department of SHNIBPS hospital, ELISA antibody titre will be done at BSMMU and CMBT and neutralizing antibody titre will be checked in collaboration with the University of Oxford. Patients who have recovered from COVID-19 will be recruited as donors of CP. The recovery criteria are normality of body temperature for more than 3 days, resolution of respiratory symptoms, two consecutively negative results of sputum SARS-CoV-2 by RT-PCR assay (at least 24 hours apart) 22 to 35 days of post onset period, and neutralizing antibody titre ≥ 1:160. INTERVENTION AND COMPARATOR: This RCT consists of three arms, a. standard care, b. standard care and 200 ml CP and c. standard care and 400 ml CP. Patients will receive plasma as a single transfusion. Intervention arms will be compared to the standard care arm. MAIN OUTCOMES: The primary outcome will be time to clinical improvement within seven days of treatment or until discharge whichever is later and in-hospital mortality. The secondary outcome would be improvement of laboratory parameters after therapy (neutrophil, lymphocyte ratio, CRP, serum ferritin, SGPT, SGOT, serum creatinine and radiology), length of hospital stay, length of ICU stay, reduction in proportion of deaths, requirement of ventilator and duration of oxygen and ventilator support. RANDOMISATION: Randomization will be done by someone not associated with the care or assessment of the patients by means of a computer generated random number table using an allocation ratio of 1:1:1. BLINDING (MASKING): This is an open level study; neither the physician nor the patients will be blinded. However, the primary and secondary outcome (oxygen saturations, PaO2/FiO2, BP, day specific laboratory tests) will be recorded using an objective automated method; the study staff will not be able to influence the recording of these data. NUMBER TO BE RANDOMISED (SAMPLE SIZE): No similar study has been performed previously. Therefore no data are available that could be used to generate a sample size calculation. This phase II study is required to provide some initial data on efficacy and safety that will allow design of a larger study. The trial will recruit 60 participants (20 in each arm). TRIAL STATUS: Protocol version 1.4 dated May 5, 2020 and amended version 1.5, dated June 16, 2020. First case was recruited on May 27, 2020. By August 10, 2020, the trial had recruited one-third (21 out of 60) of the participants. The recruitment is expected to finish by October 31, 2020. TRIAL REGISTRATION: Clinicaltrials.gov ID: NCT04403477 . Registered 26 May, 2020 FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trial's website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this letter serves as a summary of the key elements of the full protocol.
引用
- Chowdhury FR, Hoque A, Chowdhury FUH, et al. Convalescent plasma transfusion therapy in severe COVID-19 patients- a safety, efficacy and dose response study: A structured summary of a study protocol of a phase II randomized controlled trial. Trials. 2020. PMID: 33106167. doi:10.1186/s13063-020-04734-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。